Allarity Therapeutics (FRA:C6D0) FCF Margin %: -17,913.64% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:C6D0 Allarity Therapeutics Inc FRA:C6D0
26 GF Score
Price €41,491.20
! 2 Warning Signs
View Full Analysis

What is Allarity Therapeutics FCF Margin %?

Allarity Therapeutics FRA:C6D0 26 FCF Margin % is -17,913.64% as of Mar. 2026. GuruFocus rates FRA:C6D0 with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 950 Biotechnology companies, Allarity Therapeutics ranks worse than 90.32% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Allarity Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was €-3.94 Mil. Allarity Therapeutics's Revenue for the three months ended in Mar. 2026 was €0.02 Mil. Therefore, Allarity Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was -17,913.64%.

As of today, Allarity Therapeutics's current FCF Yield % is -92.84%.

The historical rank and industry rank for Allarity Therapeutics's FCF Margin % or its related term are showing as below:

FRA:C6D0' s FCF Margin % Range Over the Past 10 Years
Min: -8434.17   Med: -6533.96   Max: -4633.75
Current: -4870.51

During the past 7 years, the highest FCF Margin % of Allarity Therapeutics was -4633.75%. The lowest was -8434.17%. And the median was -6533.96%.

FRA:C6D0's FCF Margin % is ranked worse than
90.32% of 950 companies
in the Biotechnology industry
Industry Median: -81.28 vs FRA:C6D0: -4870.51

Allarity Therapeutics FCF Margin % Related Terms

Allarity Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Allarity Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allarity Therapeutics FCF Margin % Chart

Allarity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -4,638.46

Allarity Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -1,014.65 -17,913.64

FRA:C6D0 vs NCEL, LPCN, PTN: FCF Margin % Comparison

For the Biotechnology subindustry, Allarity Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allarity Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allarity Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Allarity Therapeutics's FCF Margin % falls into.


FRA:C6D0
26GF Score
Allarity Therapeutics Inc FRA:C6D0
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Allarity Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Allarity Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-12.663/0.273
=-4,638.46 %

Allarity Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-3.941/0.022
=-17,913.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -17,913.64% mean?
Allarity Therapeutics (FRA:C6D0) has a FCF Margin % of -17,913.64% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Allarity Therapeutics and its competitors. According to the industry distribution chart, Allarity Therapeutics ranks #858 out of 950 companies in the Biotechnology industry, placing it in the top 90.3%.
Is Allarity Therapeutics' FCF Margin % too high?
Allarity Therapeutics' current FCF Margin % is -17,913.64%. Based on the distribution chart, Allarity Therapeutics ranks #858 out of 950 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Allarity Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Allarity Therapeutics' FCF Margin % compare to NCEL and LPCN?
According to the Biotechnology industry distribution chart, Allarity Therapeutics ranks #858 out of 950 companies for FCF Margin %. This places Allarity Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Allarity Therapeutics and its competitors. Allarity Therapeutics's current FCF Margin % is -17,913.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allarity Therapeutics stock overvalued right now?
Allarity Therapeutics (FRA:C6D0) has a current FCF Margin % of -17,913.64%. The current FCF Margin % is -17,913.64%. Allarity Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Allarity Therapeutics (FRA:C6D0), the current FCF Margin % is -17,913.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Allarity Therapeutics Business Description

Other Exchanges ALLR:USA
Address 123 East Tarpon Avenue, Tarpon Springs, FL, USA, 34689
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
26GF Score

Get the complete analysis for FRA:C6D0

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€41,491.20
Price